{"doi":"10.1007/s00408-024-00742-x","title":"Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy","abstract":"PURPOSE: We investigated whether a 52-gene signature was associated with transplant-free survival and other clinically meaningful outcomes in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry, which enrolled patients who were and were not taking antifibrotic therapy. METHODS: The 52-gene risk signature was implemented to classify patients as being at \"high risk\" or \"low risk\" of disease progression and mortality. Transplant-free survival and other outcomes were compared between patients with a low-risk versus high-risk signature. RESULTS: The 52-gene signature classified 159 patients as at low risk and 86 as at high risk; in these groups, respectively, 56.6% and 51.2% used antifibrotic therapy at enrollment. Among those taking antifibrotic therapy, patients with a low-risk versus high-risk signature were at decreased risk of death, a composite of lung transplant or death, and a composite of decline in DLco % predicted > 15%, lung transplant, or death. Similar results were observed in the overall cohort. CONCLUSIONS: These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.","journal":"Lung","year":2024,"id":450607,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9643,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1271548,"name":"Stefan Bentink","orcid":null,"position":1,"is_corresponding":false},{"id":280049,"name":"Christian Heßlinger","orcid":null,"position":2,"is_corresponding":false},{"id":278244,"name":"Thomas B. Leonard","orcid":"0000-0003-3098-4330","position":3,"is_corresponding":false},{"id":278240,"name":"Megan L. Neely","orcid":"0000-0002-0101-1081","position":4,"is_corresponding":false},{"id":520587,"name":"Nina Patel","orcid":"0009-0001-1143-1290","position":5,"is_corresponding":false},{"id":1271100,"name":"Thomas Schlange","orcid":"0000-0002-2027-3976","position":6,"is_corresponding":false},{"id":278237,"name":"Jamie L. Todd","orcid":"0000-0003-4247-3693","position":7,"is_corresponding":false},{"id":278238,"name":"Richard Vinisko","orcid":"0000-0001-9045-3027","position":8,"is_corresponding":false},{"id":314634,"name":"Margaret L. Salisbury","orcid":"0000-0001-8217-6955","position":9,"is_corresponding":false},{"id":280047,"name":"on behalf of the IPF-PRO Registry investigators","orcid":null,"position":10,"is_corresponding":false},{"id":1271547,"name":"Julia F. Söllner","orcid":null,"position":0,"is_corresponding":true}],"reference_count":19,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:02:28.969209Z","pmid":"39242435","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}